Evidence map›Paper›PMID 41263913›Full record

Trial reportBMJ open2025

Facilitators and barriers to recruitment and retention in a feasibility trial of encapsulated faecal microbiota transplant to eradicate carriage of antibiotic-resistant bacteria at an academic hospital in central London: a nested qualitative study.

Blair Merrick, Désirée Prossomariti, Michael Kertanegara, David Wyatt, Simon Goldenberg

Abstract readRandomized Controlled Trial
In one paragraph

Trial report in BMJ open, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Blair MerrickGuy's and St Thomas' NHS Foundation Trust and King's College, London, Centre for Clinical Infection & Diagnostics Research, London, UK blair.merrick@nhs.net.ORCID http://orcid.org/0000-0002-6061-6064
Désirée ProssomaritiGuy's and St Thomas' NHS Foundation Trust and King's College, London, Centre for Clinical Infection & Diagnostics Research, London, UK.
Michael KertanegaraGuy's and St Thomas' NHS Foundation Trust and King's College, London, Centre for Clinical Infection & Diagnostics Research, London, UK.
David WyattDepartment of Population Health Sciences, King's College London, London, UK.ORCID http://orcid.org/0000-0001-5859-7389
Simon GoldenbergGuy's and St Thomas' NHS Foundation Trust and King's College, London, Centre for Clinical Infection & Diagnostics Research, London, UK.ORCID http://orcid.org/0000-0003-0837-7382

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectivesThis nested qualitative study (NQS) aimed to identify facilitators and barriers to the delivery of a substantive randomised controlled trial investigating the eradication of gastrointestinal tract carriage of antibiotic-resistant organisms using encapsulated faecal microbiota transplant (FMT).

designNQS within a participant-blinded, randomised, placebo-controlled, single-centre, feasibility trial (RCT)-Feasibility of ERadicating gastrointestinal carriage of Antibiotic-Resistant Organisms (FERARO) (ISRCTN reg. no. 34 467 677)-with data collected via focus groups and analysed using thematic analysis.

settingRCT participants were recruited from a large academic tertiary referral hospital in central London. Focus groups were held at the hospital or via videoconferencing for those unable to travel.

participantsThis study included 13 FERARO study participants across two focus groups. 11 participants were under RCT follow-up and unaware of their treatment allocation, two participants had completed 6-month follow-up and knew whether they had received FMT or matched placebo. Additional data were opportunistically collected on reasons for declining RCT participation.

resultsParticipants found FMT to be an acceptable and holistic management strategy and noted positive impacts from RCT participation including enhanced personal health awareness and valuable support from the research team. The time and travel commitment presented the most substantial barrier to RCT participation. Many participants were motivated by a desire to give something back to the UK National Health Service and/or research. Patients' current health status also influenced the decision-making process, and, while infrequently cited, the COVID-19 pandemic added extra complexity likely impacting individuals' willingness to participate.

conclusionsWhile FMT is generally acceptable to participants, logistical barriers such as the time and travel commitment associated with RCT participation need consideration. Effective communication, personal connections and participant education on antimicrobial resistance are likely to be crucial for enhancing recruitment and retention in future trials. TRIAL REGISTRATION NUMBER: ISRCTN registration number 34 467 677 and EudraCT number 2019-001618-41.

Indexed as

Carrier StateFecal Microbiota TransplantationPatient SelectionAdultAgedCOVID-19Feasibility StudiesFemaleFocus GroupsHumansLondonMaleMiddle AgedQualitative ResearchFeasibility StudiesGastrointestinal MicrobiomeMicrobiotaPatient ParticipationQUALITATIVE RESEARCH

Identifiers

PMID41263913
PMCPMC12636872

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.